NPPA Fixes Retail Price Of 74 Formulations, Details
New Delhi: Through a recent notification, the National Pharmaceutical Pricing Authority (NPPA), the Ministry of Chemicals and Fertilizer, the Government of India has fixed the retail prices of the 74 scheduled formulations including those used to lower the levels of triglycerides in blood, to prevent heart attack and stroke, to treat high blood pressure, type 2 diabetes, and gastro-oesophageal reflux disease.
This came in line with the decision of the 109th authority meeting dated 21.02.2023, where the authority discussed the new drug applications for price fixation under para 5 and 15 of DPCO 2013.
These include Exemed Pharmaceuticals & Sun Pharma's Dapagliflozin, Sitagliptin and Metformin Hydrochloride (as Extended Release) Tablets, Exemed Pharmaceuticals & Mankind Pharma's Dapagliflozin, Sitagliptin and Metformin Hydrochloride (as Extended Release) Tablets, Exemed Pharmaceuticals & Eris Lifesciences Dapagliflozin, Vildagliptin (As Sustained Release) and Metformin Hydrochloride (as Sustained Release) Tablets, Exemed Pharmaceuticals & Intas Pharmaceutical's Dapagliflozin, Vildagliptin (As Sustained Release) and Metformin Hydrochloride (as Sustained Release) Tablets.
The list further includes Ravenbhel Healthcare & Mankind Pharma's Dapagliflozin and Teneligliptin Tablets, Synokem Pharmaceuticals & Eris Lifesciences Teneligliptin, Pioglitazone and Metformin Hydrochloride (as Sustained Release) Tablets, Exemed Pharmaceuticals & Abbott Healthcare's Dapagliflozin, Vildagliptin (As Sustained Release) and Metformin Hydrochloride (as Sustained Release) Tablets etc.
This comes in exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May 2013 and S. O. 5249(E) dated 11th November 2022 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of Goods and Services Tax, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company, as specified in the corresponding entries in columns (3) and (5) thereof;
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
1 | Dapagliflozin, Sitagliptin and Metformin Hydrochloride (as Extended Release) Tablets | Each film-coated tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100mg Metformin Hydrochloride IP 500mg (as Extended Release) | 1 Tablet | M/s Exemed Pharmaceuticals / M/s Sun Pharma Laboratories Limited | 27.75 |
2 | Dapagliflozin, Sitagliptin and Metformin Hydrochloride (as Extended Release) Tablets | Each film coated tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100mg Metformin Hydrochloride IP 500mg (as Extended Release) | 1 Tablet | M/s Exemed Pharmaceuticals / M/s Mankind Pharma Ltd. | 27.75 |
3 | Dapagliflozin, Sitagliptin and Metformin Hydrochloride (as Extended Release) Tablets | Each film coated tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100mg Metformin Hydrochloride IP | 1 Tablet | M/s Exemed Pharmaceuticals / M/s Mankind Pharma Ltd. | 29.29 |
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
1000mg (as Extended Release) | |||||
4 | Dapagliflozin, Vildagliptin (As Sustained Release) and Metformin Hydrochloride (as Sustained Release) Tablets | Each film coated bilayered tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Vildagliptin IP 100mg (As Sustained Release) Metformin Hydrochloride IP 500mg (as Sustained Release) | 1 Tablet | M/s Exemed Pharmaceuticals / M/s Eris Lifesciences Limited | 14.90 |
5 | Dapagliflozin, Vildagliptin (As Sustained Release) and Metformin Hydrochloride (as Sustained Release) Tablets | Each film coated bilayered tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Vildagliptin IP 100mg (As Sustained Release) Metformin Hydrochloride IP 500mg (as Sustained Release) | 1 Tablet | M/s Exemed Pharmaceuticals / M/s Intas Pharmaceuticals Ltd. | 14.90 |
6 | Dapagliflozin, Vildagliptin (As Sustained Release) and Metformin Hydrochloride (as Sustained Release) Tablets | Each film coated bilayered tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Vildagliptin IP 100mg (As Sustained Release) Metformin Hydrochloride IP 500mg (as Sustained Release) | 1 Tablet | M/s Exemed Pharmaceuticals / M/s USV Pvt. Ltd. | 14.90 |
7 | Dapagliflozin, Vildagliptin (As Sustained Release) and Metformin Hydrochloride (as Sustained Release) Tablets | Each film coated bilayered tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Vildagliptin IP 100mg (As Sustained Release) Metformin Hydrochloride IP 500mg (as Sustained Release) | 1 Tablet | M/s Exemed Pharmaceuticals / M/s Zydus Healthcare Limited | 14.90 |
8 | Dapagliflozin, Vildagliptin (As Sustained Release) and Metformin Hydrochloride (as Sustained Release) Tablets | Each film coated bilayered tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Vildagliptin IP 100mg (As Sustained Release) Metformin Hydrochloride IP 500mg (as Sustained Release) | 1 Tablet | M/s Exemed Pharmaceuticals / M/s Cipla Ltd. | 14.90 |
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
9 | Dapagliflozin, Vildagliptin (As Sustained Release) and Metformin Hydrochloride (as Sustained Release) Tablets | Each uncoated bilayered tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Vildagliptin IP 100mg (As Sustained Release) Metformin Hydrochloride IP 500mg (as Sustained Release) | 1 Tablet | M/s Exemed Pharmaceuticals / M/s Micro Labs Limited | 14.79 |
10 | Dapagliflozin, Vildagliptin (As Sustained Release) and Metformin Hydrochloride (as Sustained Release) Tablets | Each film coated bilayered tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Vildagliptin IP 100mg (As Sustained Release) Metformin Hydrochloride IP 500mg (as Sustained Release) | 1 Tablet | M/s Exemed Pharmaceuticals / M/s Lupin Limited | 14.79 |
11 | Dapagliflozin, Vildagliptin (As Sustained Release) and Metformin Hydrochloride (as Sustained Release) Tablets | Each film coated bilayered tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Vildagliptin IP 100mg (As Sustained Release) Metformin Hydrochloride IP 500mg (as Sustained Release) | 1 Tablet | M/s Exemed Pharmaceuticals / M/s Emcure Pharmaceuticals Limited | 14.79 |
12 | Dapagliflozin, Vildagliptin (As Sustained Release) and Metformin Hydrochloride (as Sustained Release) Tablets | Each film coated bilayered tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Vildagliptin IP 100mg (As Sustained Release) Metformin Hydrochloride IP 1000mg (as Sustained Release) | 1 Tablet | M/s Exemed Pharmaceuticals / M/s Intas Pharmaceuticals Ltd. | 16.44 |
13 | Dapagliflozin, Vildagliptin (As Sustained Release) and Metformin Hydrochloride (as Sustained Release) Tablets | Each film coated bilayered tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Vildagliptin IP 100mg (As Sustained Release) Metformin Hydrochloride IP 1000mg (as Sustained Release) | 1 Tablet | M/s Exemed Pharmaceuticals / M/s Eris Lifesciences Limited | 16.44 |
14 | Dapagliflozin, Vildagliptin (As Sustained Release) and | Each film coated bilayered tablet contains: Dapagliflozin Propanediol Monohydrate eq. to | 1 Tablet | M/s Exemed Pharmaceuticals / M/s Zydus Healthcare Limited | 16.44 |
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
Metformin Hydrochloride (as Sustained Release) Tablets | Dapagliflozin 10mg Vildagliptin IP 100mg (As Sustained Release) Metformin Hydrochloride IP 1000mg (as Sustained Release) | ||||
15 | Dapagliflozin, Vildagliptin (As Sustained Release) and Metformin Hydrochloride (as Sustained Release) Tablets | Each film coated bilayered tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Vildagliptin IP 100mg (As Sustained Release) Metformin Hydrochloride IP 1000mg (as Sustained Release) | 1 Tablet | M/s Exemed Pharmaceuticals / M/s Cipla Ltd. | 16.44 |
16 | Dapagliflozin, Vildagliptin (As Sustained Release) and Metformin Hydrochloride (as Sustained Release) Tablets | Each film coated bilayered tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Vildagliptin IP 100mg (As Sustained Release) Metformin Hydrochloride IP 1000mg (as Sustained Release) | 1 Tablet | M/s Exemed Pharmaceuticals / M/s USV Pvt. Ltd. | 16.44 |
17 | Dapagliflozin, Vildagliptin (As Sustained Release) and Metformin Hydrochloride (as Sustained Release) Tablets | Each film coated bilayered tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Vildagliptin IP 100mg (As Sustained Release) Metformin Hydrochloride IP 1000mg (as Sustained Release) | 1 Tablet | M/s Exemed Pharmaceuticals / M/s Lupin Limited | 16.33 |
18 | Dapagliflozin, Vildagliptin (As Sustained Release) and Metformin Hydrochloride (as Sustained Release) Tablets | Each film coated bilayered tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Vildagliptin IP 100mg (As Sustained Release) Metformin Hydrochloride IP 1000mg (as Sustained Release) | 1 Tablet | M/s Exemed Pharmaceuticals / M/s Emcure Pharmaceuticals Limited | 16.33 |
19 | Dapagliflozin, Vildagliptin (As Sustained Release) and Metformin Hydrochloride (as Sustained Release) | Each uncoated bilayered tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Vildagliptin IP 100mg (As Sustained Release) Metformin Hydrochloride IP | 1 Tablet | M/s Exemed Pharmaceuticals / M/s Micro Labs Limited | 16.33 |
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
Tablets | 1000mg (as Sustained Release) | ||||
20 | Dapagliflozin, Vildagliptin (As Sustained Release) and Metformin Hydrochloride (as Sustained Release) Tablets | Each uncoated bilayered tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Vildagliptin IP 100mg (As Sustained Release) Metformin Hydrochloride IP 1000mg (as Sustained Release) | 1 Tablet | M/s Exemed Pharmaceuticals / M/s Abbott Healthcare Pvt. Ltd. | 16.38 |
21 | Dapagliflozin, Vildagliptin (As Sustained Release) and Metformin Hydrochloride (as Sustained Release) Tablets | Each uncoated bilayered tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Vildagliptin IP 100mg (As Sustained Release) Metformin Hydrochloride IP 500mg (as Sustained Release) | 1 Tablet | M/s Exemed Pharmaceuticals / M/s Abbott Healthcare Pvt. Ltd. | 14.84 |
22 | Sitagliptin and Metformin Hydrochloride (as Extended Release) Tablets | Each film coated bilayered tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100mg Metformin Hydrochloride IP 500mg (as Extended Release) | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd. / M/s Abbott Healthcare Pvt. Ltd. | 15.65 |
23 | Sitagliptin and Metformin Hydrochloride (as Extended Release) Tablets | Each film coated bilayered tablet contains: Sitagliptin Phosphate Monohydrate IP eq. to Sitagliptin 100mg Metformin Hydrochloride IP 500mg (as Extended Release) | 1 Tablet | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Lupin Limited | 19.45 |
24 | Teneligliptin,Pi oglitazone & Metformin Hydrochloride (Sustained Release) Tablets | Each film coated bilayered tablet contains: Teneligliptin Hydrobromide Hydrate IP eq. to Teneligliptin 20mg Pioglitazone Hydrochloride IP eq. to Pioglitazone 15mg Metformin Hydrochloride IP 500mg (As Sustained Release) | 1 Tablet | M/s Synokem Parmaceuticals Ltd. / M/s Glenmark Pharmaceuticals Limited | 16.01 |
25 | Teneligliptin, Pioglitazone and Metformin Hydrochloride (as Sustained Release) | Each Film coated bilayered tablet contains: Teneligliptin Hydrobromide Hydrate IP eq. to Teneligliptin 20mg Pioglitazone Hydrochloride | 1 Tablet | M/s Synokem Pharmaceuticals Limited / M/s Eris Lifesciences Limited | 16.01 |
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
Tablets | IP eq. to Pioglitazone 15mg Metformin Hydrochloride IP 500mg (as Sustained Release) | ||||
26 | Teneligliptin,Pioglitazone & Metformin Hydrochloride (Sustained Release) Tablets | Each film coated bilayered tablet contains: Teneligliptin Hydrobromide Hydrate IP eq. to Teneligliptin 20mg Pioglitazone Hydrochloride IP eq. to Pioglitazone 15mg Metformin Hydrochloride IP 1000mg (As Sustained Release) | 1 Tablet | M/s Synokem Parmaceuticals Ltd. / M/s Glenmark Pharmaceuticals Limited | 17.55 |
27 | Teneligliptin, Pioglitazone and Metformin Hydrochloride (as Sustained Release) Tablets | Each Film coated bilayered tablet contains: Teneligliptin Hydrobromide Hydrate IP eq. to Teneligliptin 20mg Pioglitazone Hydrochloride IP eq. to Pioglitazone 15mg Metformin Hydrochloride IP 1000mg (as Sustained Release) | 1 Tablet | M/s Synokem Pharmaceuticals Limited / M/s Eris Lifesciences Limited | 17.55 |
28 | Dapagliflozin and Teneligliptin Tablets | Each film coated tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 5mg Teneligliptin Hydrobromide Hydrate IP eq. to Teneligliptin 20mg | 1 Tablet | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Mankind Pharma Limited | 14.50 |
29 | Dapagliflozin and Teneligliptin Tablets | Each film coated tablet contains: Dapagliflozin Propanediol Monohydrate eq. to Dapagliflozin 10mg Teneligliptin Hydrobromide Hydrate IP eq. to Teneligliptin 20mg | 1 Tablet | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Mankind Pharma Limited | 15.83 |
30 | Bisoprolol Fumerate & Telmisartan Tablets | Each uncoated bilayered tablet contains: Bisoprolol Fumerate IP 2.5mg Telmisartan IP 40mg | 1 Tablet | M/s Windlas Biotech Limited / M/s Merck Specialities Pvt Ltd. | 10.92 |
31 | Telmisartan and Bisoprolol Fumarate Tablets | Each film coated tablet contains: Telmisartan IP 40mg Bisoprolol Fumarate IP 2.5mg | 1 Tablet | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Torrent Pharmaceuticals Ltd. | 10.92 |
32 | Telmisartan and Bisoprolol Fumarate Tablets | Each film coated tablet contains: Telmisartan IP 40mg Bisoprolol Fumarate IP | 1 Tablet | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Glenmark Pharmaceuticals | 10.92 |
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
2.5mg | Ltd. | ||||
33 | Telmisartan and Bisoprolol Fumarate Tablets | Each film coated tablet contains: Telmisartan IP 40mg Bisoprolol Fumarate IP 2.5mg | 1 Tablet | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Alkem Laboratories Ltd. | 10.92 |
34 | Telmisartan and Bisoprolol Fumarate Tablets | Each film coated tablet contains: Telmisartan IP 40mg Bisoprolol Fumarate IP 2.5mg | 1 Tablet | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Lupin Limited | 10.92 |
35 | Telmisartan and Bisoprolol Fumarate Tablets | Each film coated tablet contains: Telmisartan IP 40mg Bisoprolol Fumarate IP 2.5mg | 1 Tablet | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Eris lifesciences Limited | 10.92 |
36 | Telmisartan and Bisoprolol Fumarate Tablets | Each film coated tablet contains: Telmisartan IP 40mg Bisoprolol Fumarate IP 2.5mg | 1 Tablet | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Mankind Pharma Limited | 10.92 |
37 | Bisoprolol Fumerate & Telmisartan Tablets | Each uncoated bilayered tablet contains: Bisoprolol Fumerate IP 5mg Telmisartan IP 40mg | 1 Tablet | M/s Windlas Biotech Limited / M/s Merck Specialities Pvt Ltd. | 12.52 |
38 | Telmisartan and Bisoprolol Fumarate Tablets | Each film coated tablet contains: Telmisartan IP 40mg Bisoprolol Fumarate IP 5mg | 1 Tablet | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Torrent Pharmaceuticals Ltd. | 12.52 |
39 | Telmisartan and Bisoprolol Fumarate Tablets | Each film coated tablet contains: Telmisartan IP 40mg Bisoprolol Fumarate IP 5mg | 1 Tablet | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Glenmark Pharmaceuticals Ltd. | 12.52 |
40 | Telmisartan and Bisoprolol Fumarate Tablets | Each film coated tablet contains: Telmisartan IP 40mg Bisoprolol Fumarate IP 5mg | 1 Tablet | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Alkem Laboratories Ltd. | 12.52 |
41 | Telmisartan and Bisoprolol Fumarate Tablets | Each film coated tablet contains: Telmisartan IP 40mg Bisoprolol Fumarate IP 5mg | 1 Tablet | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Lupin Limited | 12.52 |
42 | Telmisartan and Bisoprolol Fumarate Tablets | Each film coated tablet contains: Telmisartan IP 40mg Bisoprolol Fumarate IP 5mg | 1 Tablet | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Eris lifesciences Limited | 12.52 |
43 | Telmisartan and Bisoprolol Fumarate Tablets | Each film coated tablet contains: Telmisartan IP 40mg Bisoprolol Fumarate IP 5mg | 1 Tablet | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Mankind Pharma Limited | 12.52 |
44 | Telmisartan and Bisoprolol Fumarate | Each film coated tablet contains: Telmisartan IP 40mg | 1 Tablet | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Abbott | 12.52 |
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
Tablets | Bisoprolol Fumarate IP 5mg | Healthcare Pvt. Ltd. | |||
45 | Telmisartan and Bisoprolol Fumarate Tablets | Each film coated tablet contains: Telmisartan IP 40mg Bisoprolol Fumarate IP 2.5mg | 1 Tablet | M/s Ravenbhel Healthcare Pvt. Ltd. / M/s Abbott Healthcare Pvt. Ltd. | 10.92 |
46 | Indacaterol and Budesonide Inhalation | Each actuation delivers: Indacaterol Maleate eq. to Indacaterol 75mcg Budesonide IP 200mcg | Per MDI | M/s Zydus Healthcare Limited | 35.22 |
47 | Indacaterol and Budesonide Powder for Inhalation | Each capsule contains: Indacaterol Maleate eq. to Indacaterol 75mcg Budesonide IP 200mcg | Per DPI | M/s Zydus Healthcare Limited | 36.22 |
48 | Indacaterol and Budesonide Powder for Inhalation | Each capsule contains: Indacaterol Maleate eq. to Indacaterol 150mcg Budesonide IP 400mcg | Per DPI | M/s Zydus Healthcare Limited | 60.71 |
49 | Atorvastatin and Clopidogrel Tablets | Each uncoated bilayere tablet contains: Atorvastatin Calcium IP eq. to Atorvastatin 40 mg Clopidogrel Bisulphate IP eq. to Clopidogrel 75 mg | 1 Tablet | M/s Pure & Cure Healthcare Pvt. Ltd. / M/s Sun Pharmaceuticals Industries Ltd. | 27.60 |
50 | Atorvastatin and Clopidogrel Tablets | Each uncoated bilayered tablet contains: Atorvastatin Calcium IP eq. to Atorvastatin 40 mg Clopidogrel Bisulphate IP eq. to Clopidogrel 75 mg | 1 Tablet | M/s Pure & Cure Healthcare Pvt. Ltd. / M/s Sun Pharma Laboratories Limited | 27.60 |
51 | Atovastatin and Clopidogrel Tablets | Each uncoated bilayered tablet contains: Atorvastatin Calcium IP eq. to Atorvastatin 40 mg Clopidogrel Bisulphate IP eq. to Clopidogrel 75 mg | 1 Tablet | M/s Pure & Cure Healthcare Pvt. Ltd. | 27.60 |
52 | Bilastine and Montelukast Ondispersible Tablets | Each uncoated Orodispersible tablet contains: Montelukast Sodium IP Eq. to Montelukast 4mg Bilastine 10mg | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Cipla Ltd. | 14.38 |
53 | Lobeglitazone Sulphate and Metformin Hydrochloride Extended- Release Tablets | Each uncoated bilayer tablet contains: Lobeglitazone Sulphate 0.5mg Metformin Hydrochloride IP 500mg (as Extended Release) | 1 Tablet | M/s Glenmark Pharmaceuticals Limited | 9.90 |
54 | Lobeglitazone Sulfate and Metformin | Each uncoated bilayer tablet contains: Lobeglitazone Sulfate 0.5mg | 1 Tablet | M/s Glenmark Pharmaceuticals Limited | 11.44 |
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
Hydrochloride Extended Release Tablets | Metformin Hydrochloride IP 1000mg (as Extended Release) | ||||
55 | Paracetamol, Phenylephrine Hydrochloride, Chlorpheniram ine maleate, Ammonium Chloride, Sodium Citrate & Menthol Suspension | Each 5ml (teaspoonful) contains: Paracetamol IP 250mg Phenylephrine Hydrochloride IP 5mg Chlorpheniramine maleate IP 2mg Ammonium Chloride IP 120mg Sodium Citrate IP 60mg Menthol IP 1mg | 1 ml | M/s Windlas Biotech Limited / M/s Torrent Pharmaceuticals Limited | 0.89 |
56 | Amoxycillin and Potassium Clavulanate Tablets IP | Each film coated tablet contains: Amoxycillin Trihydrate eq. to Amoxycillin IP 875mg Potassium Clavulanate Diluted eq. to Clavulanic Acid IP 125mg | 1 Tablet | M/s Alps Communications Pvt. Ltd. / M/s Aristo Laboratories Pvt. Ltd. | 34.68 |
57 | Amoxycillin and Potassium Clavulanate Oral suspension | Each 5ml reconstituted suspension contains: Amoxycillin Trihydrate eq. to Amoxycillin IP 400mg Potassium Clavulanate Diluted eq. to Clavulanic Acid IP 57mg | 1 ml | M/s Alps Communications Pvt. Ltd. / M/s Aristo Laboratories Pvt. Ltd. | 3.97 |
58 | Cefixime and Ofloxacin Tablets | Each film coated tablet contains: Cefixime eq. to Cefixime Anhydrous IP 200mg Ofloxacin IP 200mg | 1 Tablet | M/s Alps Communications Pvt. Ltd. / M/s Aristo Laboratories Pvt. Ltd. | 12.74 |
59 | Bilastine and Montelukast Oral Suspenssion | Each 5ml suspension contains: Bilastine 10mg Montelukast Sodium IP eq. to Monelukast 4mg | 1 ml | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Zuventus Healthcare Limited | 1.71 |
60 | Bilastine and Montelukast Oral Suspenssion | Each 5ml suspension contains: Bilastine 10mg Montelukast Sodium IP eq. to Monelukast 4mg | 1 ml | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Emcure Pharaceuticals Limited | 1.71 |
61 | Amoxycillin & Potassium Clavulanate Oral Suspension IP 457mg | Each 5ml of reconstituted suspension contains: Amoxycillin trihydrate IP eq. to Amoxycillin 400mg Potassium Clavulanate Diluted IP eq. to Clavulanic Acid 57mg | 1 ml | M/s Medicef Pharma / M/s Troikaa Pharmaceuticals Ltd. | 3.90 |
62 | Dextromethorphan hydrobromide, | Each 5ml contains: Dextromethorphan Hydrobromide IP 5mg | 1 ml | M/s Pure and Cure Healthcare Pct. Ltd. / M/s German | 0.86 |
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
Chlorpheniram ine Meleate & Phenylephrine Hydrochloride Syrup | Chlorpheniramine Meleate IP 1mg Phenylephrine Hydrochloride IP 2.5mg | Remedies Pharmaceuticals Pvt. Ltd. | |||
63 | Dextromethor phan hydrobromide, Chlorpheniram ine Meleate & Phenylephrine Hydrochloride Syrup | Each 5ml contains: Dextromethorphan Hydrobromide IP 15mg Chlorpheniramine Meleate IP 2mg Phenylephrine Hydrochloride IP 5mg | 1 ml | M/s Pure and Cure Healthcare Pct. Ltd. / M/s German Remedies Pharmaceuticals Pvt. Ltd. | 0.87 |
64 | Aceclofenac, Paracetamol & Serratiopeptid ase Tablets | Each Film Coated Tablet contains: Aceclofenac IP 100mg Paracetamol IP 325mg Serratiopeptidase IP 15mg | 1 Tablet | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s Torrent Pharmaceuticals Ltd. | 7.78 |
65 | Desvenlafaxine Extended release and Clonazepam Tablets | Each uncoated bilayered tablet contains: Desvenlafaxine Succinate USP eq. to Desvenlafaxine 50mg (As Extended release form) Clonazepam IP 0.25mg | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd. | 13.24 |
66 | Trastuzumab 150mg | Combipack of Each pack contains: Vial-I Lyophilized Powder for concentrate for solution for Intravenous Infusion, Multi use vial Composition: Trastuzumab (r-DNA Origin) IH (Active ingredient) 150mg, α,α-Trehalose Dihydrate USP (as Lyoprotectant) 136.2mg L-Histidine Hydrochloride Monohydrate EP (as buffering agent) 3.36mg L-Histidine USP (as buffering agent) 2.16mg Polysorbate 20 IP (as surfactant) 0.6mg Vial -2 Bacteriostatic Water for Injection 10 ml Single use vial Composition: Benzyl Alcohol IP 1.1% V/V Water for Injection | 1 ml | M/s Hetero Biopharma Ltd. / M/s Hetero Healthcare Ltd. | 15522. 32 |
67 | Aceclofenac, Paracetamol | Each Film Coated Tablet contains: | 1 Tablet | M/s Theon Pharmaceuticals | 7.78 |
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
and Serratiopeptid ase tablets | Aceclofenac IP 100mg Paracetamol IP 325mg Serratiopeptidase IP 15mg | Limited / M/s Zydus Healthcare Limited | |||
68 | Trypsin- Chymotrypsin, Paracetamol & Aceclofenac Tablets | Each Film coated tablet contains: 50000 Armour Units of Enzymatic Activity (Supplied by a Purified Concentrate which has specific Trypsin & Chymotrypsin Activity in a Ratio of Approximately Six One)(As enteric coated granules) Paracetamol IP 325 Aceclofenac IP 100mg | 1 Tablet | M/s Biogenetic Drugs Pvt. Ltd. / M/s Lupin Limited | 9.84 |
69 | Cilnidipine, Telmisartan & Chlorthalidone Tablets | Each film coated tablet contains: Cilnidipine IP 10mg Telmisartan IP 40mg Chlorthalidone IP 12.50mg | 1 Tablet | M/s Pure and Cure Healthcare Pvt. Ltd. / M/s Aristo Pharmaceuticals Pvt. Ltd. | 13.72 |
70 | Paclitaxel (protein bound particles) for Injectable Suspension (Lyophilized) | Each Vial contains: Paclitaxel IP 100mg Human Albumin IP approximately 900mg (After reconstitution) | 1 vial | M/s Samarth Life Sciences Pvt. Ltd. | 5866.7 6 |
71 | Ferrous Fumarate, Folic Acid and Cyanocobalami n Syrup | Each 5ml contains: Ferrous Fumarate IP 100mg eq. to Elemental Iron 32.8mg Folic Acid IP 0.5mg Cyanocobalamin (Vitamin B12) IP5mcg | I ml | M/s Zydus Healthcare Limited | 0.55 |
72 | Amoxycillin and Potassium Clavulanate Tablets IP | Each film coated tablet contains: Amoxycillin Trihydrate eq. to Amoxycillin IP 250mg Potassium Clavulanate Diluted eq. to Clavulanic Acid IP 125mg | 1 Tablet | M/s Alps Communications Pvt. Ltd. / M/s Aristo Laboratories Pvt. Ltd. | 16.15 |
73 | Amoxycillin, Dicloxacillin & Lactic Acid Bacillus Capsule | Each hard gelation contains: Amoxycillin Trihydrate IP eq. to Amoxycillin 250mg Dicloxacillin Sodium IP eq. to Dicloxacillin 250mg Lactic Acid Bacillus 2.5 billion Spores | 1 Capsule | M/s Akums Drugs & Pharmaceuticals Ltd. / M/s German Remedies Pharmaceuticals Private Limited | 8.77 |
74 | Multivitamin Tablets with Mineral and Trace Element | Each sugar coated tablet contains: Vitamin A (As Acetate) IP 10000 IU. Cholecalciferol IP 1000 IU (In Stabilized form… ) Thiamine Mononitrate IP 10mg | 1 Tablet | M/s Aristo Pharmaceuticals Pvt. Ltd. | 1.88 |
Sl. No. | Name of the Formulation / Brand Name | Strength | Unit | Manufacturer & Marketing Company | Retail Price (Rs.) |
(1) | (2) | (3) | (4) | (5) | (6) |
Riboflavin IP 10mg Pyridoxine Hydrochlorie IP 3mg Cyanocobalamin IP 15mcg Nicotinaminde IP 100mg Calcium Pantothenate IP 16.30mg Ascorbic Acid IP 150mg α Tocopheryl Acetate IP 25mg Biotin USP 0.25mg Tribasic Calcium Phosphate IP 129mg Light Magnesium Oxide IP 60mg Dried Ferrous Sulphate IP 32.04mg Manganese Sulphate Monohydrate BP 2.03mg Total Phosphorus in the preparation 25.80mg Copper Suphate Pentahydrate BP 3.39mg Zinc Sulphate IP 2.20mg Sodium Molybdate Dihydrate BP 0.25mg Sodium Borate BP 0.88mg |
Note:
(a) The manufacturer of the above-mentioned formulations i.e., “new drug” under paragraph 2(1)(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
(b) The manufacturer may add Goods and Services Tax only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above-said table.
(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from the date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display the price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
(e) The above-mentioned retail price is applicable only to the individual manufacturer/marketer as mentioned above i.e. who has applied for the same by submitting Form-I for price fixation/revision as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturer/marketing companies.
(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
(g) Consequent to the fixation of the retail price of such formulation as specified in column (2) of the above table with the strength and name of Manufacturer & Marketing Companies specified in the corresponding entries in Columns (3) & (5) thereof, the price order(s) fixing the retail price of the formulation with specified strength for that Manufacturer & Marketing Companies as specified in corresponding entries in Column (2), (3) and (5) thereof, if any, issued prior to this notification, stand(s) superseded.
Also Read: CDSCO panel nod to Sun Pharma to manufacture, market antidiabetic FDC drug
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd